Table 3.
Correlation between age at first intercourse rates of HPV infection and high-grade cervical disease (CIN2 or worse).
| Age at first intercourse | n | (%pos) | Univariate | Multivariate | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |||||||||||||
| OR | (95% CI) | P value | aOR | (95% CI) | P value | aOR | (95% CI) | P value | aOR | 95% (CI) | P value | ||||
| High-risk HPVa | ≤ 14 | 29/109 | (26.6) | Reference | – | Reference | – | Reference | – | Reference | – | ||||
| 15–16 | 128/779 | (16.4) | 0.5 | (0.3–0.9) | 0.01 | 0.6 | (0.4–0.9) | 0.02 | 0.7 | (0.4–1.1) | 0.09 | 0.8 | (0.5–1.4) | 0.46 | |
| 17–19 | 176/1441 | (12.2) | 0.4 | (0.2–0.6) | < 0.01 | 0.5 | (0.3–0.7) | < 0.01 | 0.6 | (0.4–1.0) | 0.04 | 1.1 | (0.7–1.8) | 0.77 | |
| ≥ 20 | 67/902 | (7.4) | 0.2 | (0.1–0.4) | < 0.01 | 0.3 | (0.2–0.5) | < 0.01 | 0.4 | (0.2–0.7) | < 0.01 | 1.2 | (0.7–2.1) | 0.54 | |
| P for trend | < 0.01 | < 0.01 | < 0.01 | 0.09 | |||||||||||
| HPV16/18 | ≤ 14 | 5/109 | (4.6) | Reference | – | Reference | – | Reference | – | Reference | – | ||||
| 15–16 | 23/779 | (3.0) | 0.6 | (0.2–1.6) | 0.30 | 0.6 | (0.2–1.7) | 0.38 | 0.7 | (0.3–1.9) | 0.51 | 1.0 | (0.4–2.8) | 0.99 | |
| 17–19 | 36/1441 | (2.5) | 0.5 | (0.2–1.3) | 0.13 | 0.6 | (0.2–1.6) | 0.29 | 0.7 | (0.3–2.0) | 0.56 | 1.8 | (0.7–5.1) | 0.24 | |
| ≥ 20 | 12/902 | (1.3) | 0.2 | (0.1–0.7) | 0.01 | 0.3 | (0.1–0.9) | 0.04 | 0.4 | (0.1–1.3) | 0.15 | 2.6 | (0.8–8.6) | 0.11 | |
| P for trend | < 0.01 | 0.03 | 0.16 | 0.01 | |||||||||||
| HPV16/18/31/33/45/52/58 | ≤ 14 | 15/109 | (13.8) | Reference | – | Reference | – | Reference | – | Reference | – | ||||
| 15–16 | 78/779 | (10.0) | 0.7 | (0.4–1.2) | 0.19 | 0.7 | (0.4–1.3) | 0.30 | 0.9 | (0.5–1.6) | 0.60 | 1.1 | (0.6–2.1) | 0.75 | |
| 17–19 | 102/1441 | (7.1) | 0.5 | (0.3–0.8) | 0.01 | 0.6 | (0.3–1.0) | 0.06 | 0.8 | (0.4–1.4) | 0.40 | 1.5 | (0.8–2.9) | 0.20 | |
| ≥ 20 | 36/902 | (4.0) | 0.2 | (0.1–0.5) | < 0.01 | 0.3 | (0.2–0.6) | < 0.01 | 0.5 | (0.2–1.0) | 0.04 | 1.9 | (0.9–3.9) | 0.10 | |
| P for trend | < 0.01 | < 0.01 | 0.01 | 0.02 | |||||||||||
| CIN2 or worse | ≤ 14 | 5/109 | (4.6) | Reference | – | Reference | – | Reference | – | Reference | – | ||||
| 15–16 | 17/779 | (2.2) | 0.4 | (0.2–1.2) | 0.09 | 0.4 | (0.2–1.2) | 0.10 | 0.5 | (0.2–1.3) | 0.15 | 0.6 | (0.2–1.7) | 0.32 | |
| 17–19 | 19/1441 | (1.3) | 0.3 | (0.1–0.7) | 0.01 | 0.3 | (0.1–0.8) | 0.01 | 0.3 | (0.1–1.0) | 0.05 | 0.6 | (0.2–1.9) | 0.42 | |
| ≥ 20 | 6/902 | (0.7) | 0.1 | (0.0–0.4) | < 0.01 | 0.1 | (0.0–1.5) | < 0.01 | 0.2 | (0.1–0.7) | 0.01 | 0.7 | (0.2–2.7) | 0.59 | |
| P for trend | < 0.01 | < 0.01 | 0.01 | 0.80 | |||||||||||
CIN cervical intraepithelial neoplasia, OR odds ratio, aOR adjusted odds ratio.
Model 1 adjusted for age.
Model 2 adjusted for age and smoking history.
Model 3 adjusted for age, smoking history and number of lifetime sexual partners.
aHPV16/18/31/33/35/39/45/51/52/56/58/59/68 (HC2).